Drug
Berotralstat clinical trials
Also written BCX7353 and Orladeyo®.
- studies test it
- 10
- open now
- 1
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the berotralstat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses berotralstat is read from its arms, and is right about nine times in ten.
Testing it · 10
- Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesEnrolling by invitationPhase 3BioCryst PharmaceuticalsNCT04933721Written as berotralstat
- Berotralstat Treatment in Children With Hereditary AngioedemaActive, not recruitingPhase 3BioCryst PharmaceuticalsNCT05453968Written as Berotralstat
- Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedPhase 3BioCryst PharmaceuticalsNCT03873116Written as BCX7353 capsules
- Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAECompletedPhase 3BioCryst PharmaceuticalsNCT03485911Written as BCX7353 capsules
- A Long Term Safety Study of BCX7353 in Hereditary AngioedemaCompletedPhase 2/3BioCryst PharmaceuticalsNCT03472040Written as BCX7353
- Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaCompletedPhase 2BioCryst PharmaceuticalsNCT03240133Written as BCX7353
- Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaCompletedPhase 2BioCryst PharmaceuticalsNCT02870972Written as BCX7353
- A Relative Bioavailability Study of Two Formulations of BCX7353CompletedPhase 1BioCryst PharmaceuticalsNCT03202784Written as BCX7353
- A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedPhase 1BioCryst PharmaceuticalsNCT03136237Written as BCX7353
- First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCompletedPhase 1BioCryst PharmaceuticalsNCT02448264Written as BCX7353
Codes
What other systems call berotralstat · ClinicalTrials.gg INT001323
- MeSH (NLM) C000706836berotralstatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) XZA0KB1BDQBEROTRALSTATConfirmed FDA, NLM, Wikidata
- RxNorm 2467540One source FDA
- Wikidata Q104529366berotralstatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169808BerotralstatOne source FDA
- DrugBank DB15982One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706836 | berotralstat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | XZA0KB1BDQ | BEROTRALSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2467540 | — | One source FDA |
| Wikidata | Q104529366 | berotralstat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169808 | Berotralstat | One source FDA |
| DrugBank | DB15982 | — | One source Wikidata |
Also registered as berotralstat hydrochloride (UNII 88SH1NBL2B · RxNorm 2467541).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.